Innoviva Total Current Liabilities 2010-2024 | INVA
Innoviva total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Innoviva Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$38 |
| 2022 |
$135 |
| 2021 |
$6 |
| 2020 |
$6 |
| 2019 |
$5 |
| 2018 |
$6 |
| 2017 |
$35 |
| 2016 |
$20 |
| 2015 |
$13 |
| 2014 |
$14 |
| 2013 |
$84 |
| 2012 |
$30 |
| 2011 |
$45 |
| 2010 |
$40 |
| 2009 |
$39 |
Innoviva Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$28 |
| 2024-03-31 |
$30 |
| 2023-12-31 |
$38 |
| 2023-09-30 |
$36 |
| 2023-06-30 |
$39 |
| 2023-03-31 |
$38 |
| 2022-12-31 |
$135 |
| 2022-09-30 |
$164 |
| 2022-06-30 |
$126 |
| 2022-03-31 |
$109 |
| 2021-12-31 |
$6 |
| 2021-09-30 |
$3 |
| 2021-06-30 |
$5 |
| 2021-03-31 |
$4 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$5 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$5 |
| 2019-09-30 |
$3 |
| 2019-06-30 |
$7 |
| 2019-03-31 |
$4 |
| 2018-12-31 |
$6 |
| 2018-09-30 |
$4 |
| 2018-06-30 |
$7 |
| 2018-03-31 |
$4 |
| 2017-12-31 |
$35 |
| 2017-09-30 |
$33 |
| 2017-06-30 |
$27 |
| 2017-03-31 |
$20 |
| 2016-12-31 |
$20 |
| 2016-09-30 |
$15 |
| 2016-06-30 |
$15 |
| 2016-03-31 |
$11 |
| 2015-12-31 |
$13 |
| 2015-09-30 |
$11 |
| 2015-06-30 |
$12 |
| 2015-03-31 |
$11 |
| 2014-12-31 |
$14 |
| 2014-09-30 |
$36 |
| 2014-06-30 |
$50 |
| 2014-03-31 |
$44 |
| 2013-12-31 |
$84 |
| 2013-09-30 |
$39 |
| 2013-06-30 |
$39 |
| 2013-03-31 |
$29 |
| 2012-12-31 |
$30 |
| 2012-09-30 |
$27 |
| 2012-06-30 |
$26 |
| 2012-03-31 |
$26 |
| 2011-12-31 |
$45 |
| 2011-09-30 |
$40 |
| 2011-06-30 |
$35 |
| 2011-03-31 |
$33 |
| 2010-12-31 |
$40 |
| 2010-09-30 |
$36 |
| 2010-06-30 |
$36 |
| 2010-03-31 |
$36 |
| 2009-12-31 |
$39 |
| 2009-09-30 |
$39 |
| 2009-06-30 |
$40 |
| 2009-03-31 |
$37 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.222B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
